A Phase 2 clinical trial in China has demonstrated promising, durable responses to relmacabtagene autoleucel (relma-cel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, for patients with relapsed or refractory…
You can read the full story here: Relma-Cel Shows Promise in Relapsed/Refractory MCL – China Phase 2 Data .